Year: 2022
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND AIMS: Etiological risk factors for cirrhosis have changed in the last decade. It remains unclear to what extent these trends in cirrhosis risk factors have changed HCC risk. APPROACH AND RESULTS: We used data from two contemporary, prospective multiethnic cohorts of patients with cirrhosis: the Texas Hepatocellular Carcinoma Consortium Cohort and the Houston Veterans Administration Cirrhosis Surveillance Cohort. Patients with cirrhosis were enrolled from seven US centers and followed until HCC diagnosis, transplant, death, or June 30, 2021. We calculated the annual incidence rates for HCC and examined the effects of etiology, demographic, clinical, and lifestyle factors on the risk of HCC. We included 2733 patients with cirrhosis (mean age 60.1 years, 31.3% women). At enrollment, 19.0% had active HCV, 23.3% had cured HCV, 16.1% had alcoholic liver disease, and 30.1% had NAFLD. During 7406 person-years of follow-up, 135 patients developed HCC at an annual incidence rate of 1.82% (95% CI, 1.51-2.13). The annual HCC incidence rate was 1.71% in patients with cured HCV, 1.32% in patients with alcoholic liver disease, and 1.24% in patients with NAFLD cirrhosis. Compared to patients with NAFLD, the risk of progression to HCC was 2-fold higher in patients with cured HCV (HR, 2.04; 95% CI, 1.24-3.35). Current smoking (HR, 1.63; 95% CI, 1.01-2.63) and overweight/obesity (HR, 1.79; 95% CI, 1.08-2.95) were also associated with HCC risk. CONCLUSIONS: HCC incidence among patients with cirrhosis was lower than previously reported. HCC risk was variable across etiologies, with higher risk in patients with HCV cirrhosis and lower risk in those with NAFLD cirrhosis. Current smoking and overweight/obesity increased HCC risk across etiologies.
Source: Hepatology
DOI: 10.1002/hep.32434
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Cancer Prevention and Research Institute of Texas, Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Center for Innovations in Quality, Effectiveness and Safety, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G111615301, G1139922818, G1147702603, G1292721935, G1376554346, G1685493032, G209472043, G300014730, G3272752000, G4553610997, G456856876, G4966895449, Studies of Childhood Solid Tumors, The Texas Hepatocellular Carcinoma Consortium (THCCC), G5891413035, G6182568868, G6334581636, G6751607210, Cancer Center Support Grant, Consortium on Translational Research in Early Detection of Liver Cancer:Data Management and Coordinating Center (DMCC), G931170033
OpenAlex ID: W4214758114